Liz, a 37-year-old woman with HIV, is receiving her 2nd dose of MCV4. Which recommendation is appropriate for her MCV4 vaccination?

In the case of Liz, a woman with HIV who is receiving her second dose of the meningococcal conjugate vaccine (MCV4), the recommendation to revaccinate every 5 years is appropriate due to her immunocompromised status. Individuals with HIV, especially those with a CD4 count below 200 cells/mm³ or who have symptomatic disease, are considered at increased risk for meningococcal disease. Therefore, it's crucial to ensure that they are adequately protected.

Revaccination every 5 years for those at heightened risk helps maintain immunity against meningococcal disease, as the protection offered by the vaccine can decline over time. This interval is specified in the guidelines for patients who have underlying conditions that predispose them to higher risks of infections, including those with HIV.

This strategy balances the need to continue providing protection against meningococcal disease while taking into account the unique health circumstances of immunocompromised patients.